Good news is more than a year away. If it happens at all.
People are not buying. A few funds are required to include MNTA in the portfolio, and with the market up 200 plus the funds are buying the basket.
Could be short covering. Short interest down 25% in the last month to a one year low.
I am accumulating while waiting
1. baxter /grifols taking out momenta after new sivig/sfc data
2) momenta already shifted focus from the enoxaparin quagmire, the followup patents
will be more ironclad
3) for more nonsensical favoritism filed against woodcock when m-glatiramer gets the nod
4) when amphastar-watson fubar srouce tainted batches of heparin (like baxter), to see their science (or lack thereof) in resolving the situation